



June 16, 2011

Federal Communications Commission  
Authorization and Evaluation Division

**Philips Healthcare**

22100 Bothell Everett Hwy  
Bothell, WA 98021-8431

Confidentiality Request regarding application for certification of FCC ID: PQC-M3813C

Pursuant to Sections 0.457 and 0.459 of the Commission's Rules, we hereby request confidential treatment of information accompanying this application as outlined below:

<b>Exhibit Type</b>	<b>File Name</b>
Block Diagram	PQC-M3813C BlkDia.pdf
Schematics	PQC-M3813C Schem.pdf
Operational Description	PQC-M3813C OpDes.pdf

The above materials contain trade secrets and proprietary information not customarily released to the public. The public disclosure of these materials may be harmful to the applicant and provide unjustified benefits to its competitors.

The applicant understands that pursuant to Section 0.457 of the Rules, disclosure of this application and all accompanying documentation will not be made before the date of the Grant for this application.

Pursuant to DA04-1705 June 15, 2004 of the Commission's public notice, we also require temporary confidential treatment of information accompanying this application as outlined below:

<b>Exhibit Type</b>	<b>File Name</b>
Internal Photos	PQC-M3813C IntPho.pdf

Temporary confidentiality from public disclosure is important for Philips Medical Systems from a commercial perspective. It enables the company to complete its development and regulatory efforts prior to introducing the product to the marketplace. Releasing information on the product via the FCC website prior to formal market introduction can be confusing to our customers and the medical community, and places the company at a competitive disadvantage.

Sincerely,

Terrence Sweeney  
Vice President – Global Clinical Affairs